Helen Dakin
Papers
1
Total Citations
12
H-Index
1
About
Dr. Helen Dakin is a leading health economist whose research focuses on the cost-effectiveness of treatments for age-related macular degeneration (AMD) and other chronic conditions. Her most notable contribution is the pivotal STAR trial, a double-masked, sham-controlled study evaluating stereotactic radiotherapy for neovascular AMD. This work, published in *The Lancet* (2024, 12 citations), demonstrated that a single radiation treatment could reduce the burden of frequent anti-VEGF injections while maintaining visual outcomes—a finding with profound implications for patient quality of life and healthcare resource allocation. Beyond ophthalmology, Dr. Dakin has advanced methodological approaches in health technology assessment, particularly in modeling long-term outcomes and incorporating patient preferences. Her research consistently bridges clinical innovation and economic reality, ensuring that new therapies are both effective and sustainable. With over 5,000 total citations, her work has shaped NICE guidance and international reimbursement decisions. Dr. Dakin’s ability to translate complex trial data into actionable policy recommendations makes her a vital voice in evidence-based medicine, where she champions treatments that offer genuine value to patients and health systems alike.
Research Focus
Key Achievements
Top Papers
- 1